Adaptimmune up on promise of low-dose radiation to aid SPEAR T-cell therapy

Thinly traded micro cap Adaptimmune Therapeutics plc (ADAP +10.4%) is up on modestly higher volume, albeit on turnover of only 306K shares, in reaction to the initiation of a 10-subject radiation sub-study evaluating its ADP-A2M4 SPEAR T cells in patients with solid tumors.

The company says published data show that low-dose radiation may enhance T-cell responses in these patients.

It expects to launch a new trial, SPEARHEAD-1, assessing ADP-A2M4 in sarcoma patients later this year.

https://seekingalpha.com/news/3479758-adaptimmune-10-percent-promise-low-dose-radiation-improve-spear-t-cell-therapy